newsfilter
← Latest News
Business Wire·

bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung

BIAFBIAFW
  • bioAffinity Technologies reported CyPath Lung test volume increased 216% year-over-year in Q2 2026.
  • CyPath Lung testing revenue for the first six months of 2026 rose 159% to approximately $835,000.
  • The company delivered 1,097 CyPath Lung test reports in the first half of 2026, up from 390 in the same period of 2025.
  • The number of physician offices ordering CyPath Lung increased 122% in Q2 2026 compared to the prior year.
  • Existing clients increased their CyPath Lung orders by 71% year-over-year during the first six months of 2026.
  • A longitudinal clinical trial evaluating CyPath Lung began enrollment at 11 sites, including nine VA & military centers, with funding from the Murtha Cancer Center Research Program.
  • Positive preliminary data supports developing topical siRNA therapeutics for squamous, basal, & melanoma skin cancers.
  • The company advanced a diagnostic platform to identify antibody drug receptors in sputum for matching asthma & COPD therapies.
  • bioAffinity published a clinical review by CMO Gordon H. Downie, MD, PhD, on incorporating CyPath Lung into pulmonary nodule evaluation.
  • A collaboration with Pictor, Inc. was announced to develop next-generation diagnostics for lung inflammation in asthma & COPD patients.
  • The company received patent allowance from Mexico for using defined antibodies & flow cytometry to detect lung cancer cells in sputum.
  • A public offering completed in June 2026 generated approximately $3.2 million in gross proceeds.
  • Q2 2026 revenue was $1.5 million, a 19% increase from $1.3 million in Q2 2025.
  • Operating expenses for Q2 2026 were $4.8 million, compared to $3.8 million in Q2 2025.
  • Research & development expenses increased 16% to $362,000, driven by lab relocation costs.
  • Clinical development expenses rose to $476,000 due to initiating the longitudinal clinical study.
  • Selling, general & administrative expenses increased to $2.9 million, primarily due to added sales & administrative personnel.
  • Net loss for Q2 2026 was $3.4 million, improving from a $4.1 million loss in Q2 2025.
  • Cash & cash equivalents as of June 30, 2026, were $2.4 million, down from $6.4 million as of December 31, 2025.
  • CyPath Lung demonstrated 92% sensitivity, 87% specificity, 88% accuracy, & 99% negative predictive value in detecting lung cancer in high-risk patients.
  • The company faces risks including a Nasdaq delisting determination notice which is being appealed.